06 Jun FDA Approves the Next Best thing for Opioid Addiction
‘Lucemyra’ could be the next best thing in addiction treatment
By, Ivy Chase.
Opioid Addiction is at an all time high in America, it’s been claimed a complete state of crisis for the nation. A non opioid drug called Lucemra has been approved by the FDA to mitigate withdrawal symptoms after abrupt discontinued use of opioids.
Part of the turn off for individuals who go off opioid painkillers and even harsher opiates is the idea of facing the excruciating withdrawal symptoms such as nausea, anxiety, vomiting, muscle aches and more, most resembling a terrible flu bug. Currently, the FDA has given it’s approval for US World Meds new medication called Lucemyra, the first drug designed to fight the opioid withdrawal symptoms.
The drug was approved after showing that it reduced severe withdrawal symptoms better than the placebo did. Individuals who participated in the drug trial, consuming the drug completed a seven day opioid discontinuation treatment. These symptoms were a vast improvement from the group of participants who took the placebo.
The New Concept of the lack of suffering
The UK has been using Lucemyra for more than two decades. They have said that the drug (which is administered orally), isn’t meant to treat opioid addiction or curb drug cravings, however it is most effectively used as part of a long term plan or treatment for quitting powerful painkillers and staying opioid-free long term, commented the FDA on it’s benefits.
Long term medication assisted addiction therapy such as the Vivitrol shot or Naltrrexone blocks the effects of opioids on the brain, thus one cannot feel the effects or euphoria of the drugs. Lucemyra works by reducing and releasing norepinephrine, the very chemical believed to play such a large role in causing the body withdrawal symptoms.
The withdrawal effects from opioids is usually the main or most terrifying barrier which individuals who are physically addicted face when trying to become clean and sober, ultimately overcoming addiction. One addicted, they become filled with mainly the overwhelming fear of going through the withdrawal symptoms, which is often the reason that prevents them from recovering and ending the pain and suffering of addiction in the first place.
Because this new drug will make the withdrawal process easier for addicts trying to recover, National Institute on Drug Abuse Director Nora Valkow, MD, argues that the drug may promote an increase and a wider use of Vivitrol, a drug that differentiates itself from methadone and buprenorphine- a couple other addiction treatments that belong to the opioid family.
America’s Solution to the Opioid Crises?
The FDA has approved Lucemyra the go ahead towards the treatment of withdrawal from Opioid addiction, claiming thousands of individuals struggling will be able to finally overcome their fear of withdrawal. Currently the medication is only approved for up to 14 days of use. The agency will continue to examine the drug’s long term effects and effectiveness.
The launch of Lucemyra is projected in the U.S. in August 2018.